Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

NCT07708727 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: GS-3242 Tablet
DRUG: GS-3242 Injection
DRUG: Lenacapavir Tablet
DRUG: Lenacapavir Injection
DRUG: B/F/TAF

Sponsor

Gilead Sciences